{"doi":"10.1016/j.ijbiomac.2022.06.167","title":"Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment","abstract":null,"journal":"International Journal of Biological Macromolecules","year":2022,"id":645471,"datarank":0.3596842909197557,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"self_citation_contribution":0.3596842909197557,"citation_network_contribution":0.0,"self_endowment_contribution":0.3596842909197557,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":10,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1680747,"name":"Mingyue Jiang","orcid":null,"position":1,"is_corresponding":false},{"id":967607,"name":"Xiaoxue Fu","orcid":"0000-0002-6124-731X","position":2,"is_corresponding":false},{"id":889554,"name":"Jiaxin Yang","orcid":"0000-0002-7925-6935","position":3,"is_corresponding":false},{"id":625526,"name":"Lu Chen","orcid":"0000-0003-2906-2507","position":4,"is_corresponding":false},{"id":1680748,"name":"Feng Leng","orcid":null,"position":5,"is_corresponding":false},{"id":369303,"name":"Ping Xu","orcid":"0000-0002-4652-4841","position":6,"is_corresponding":false},{"id":1680749,"name":"Wenyan Huang","orcid":null,"position":7,"is_corresponding":false},{"id":1111673,"name":"Chao Yu","orcid":"0000-0001-5781-1363","position":8,"is_corresponding":false},{"id":1680750,"name":"Zhangyou Yang","orcid":null,"position":9,"is_corresponding":false},{"id":1680746,"name":"Weihong Jing","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment","abstract":"Nonalcoholic fatty liver disease (NAFLD) is a chronic metabolic liver disease closely related to obesity, which has become a global health problem. However, current pharmacological therapies for NAFLD are limited by potential side effects, low effectiveness and poor aqueous solubility. Herein, we designed functionalized drug-albumin nanocomposites (BAM15@BSA NPs), which were prepared by self-assembly of the anti-obesity small-molecule drug (BAM15) and bovine serum albumin (BSA), for treatment of NAFLD. The proposed BAM15@BSA NPs not only improve aqueous solubility and half-life of BAM15 but also exhibit hepatic-targeted capacity and an increased therapeutic efficacy. In vitro experiments revealed that BAM15@BSA NPs possessed excellent biocompatibility, and improved resistance to adipogenesis and reduced lipid accumulation in human hepatocellular carcinoma cells. In vivo, BAM15@BSA NPs showed liver targeting ability and powerful anti-obesity effects without altering body temperature or affecting food intake, and could effectively alleviate hepatic steatosis and improve therapeutic efficacy for NAFLD treatment. The above findings demonstrated that BAM15@BSA NPs potentially served as a safe and effective drug for NAFLD treatment.","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35777511","pmcid":null,"openalex_id":"https://openalex.org/W4283695061","authors":[],"funders":[{"funder_name":"Chongqing Medical University","grant_id":"YXY2019QNGD1","title":null},{"funder_name":"Natural Science Foundation of Chongqing","grant_id":"cstc2021jcyj-msxmX0246","title":null}],"total_grants":2,"fwci":0.8801,"citation_percentile":0.72138083,"influential_citations":0,"citation_trend":[{"year":2023,"count":1},{"year":2024,"count":2},{"year":2025,"count":3},{"year":2026,"count":4}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0141813022013800?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0141813022013800?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ijbiomac.2022.06.167","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35777511","host_type":"repository"}],"fields_of_study":["Liver Disease Diagnosis and Treatment","Endoplasmic Reticulum Stress and Disease","Alcohol Consumption and Health Effects"],"mesh_terms":["Humans","Liver","Obesity","Serum Albumin, Bovine","Anti-Obesity Agents","Nanocomposites","Non-alcoholic Fatty Liver Disease"],"keywords":["Nonalcoholic fatty liver disease","Steatosis","Albumin","Drug","In vivo","Serum albumin","Pharmacology","Liver disease","Bovine serum albumin","Fatty liver","Medicine","Chronic liver disease","Chemistry","Internal medicine","Biochemistry","Disease","Biology","Biotechnology","Obesity","Self-assembly","Bam15","Drug-albumin Nanocomposites"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T06:07:53.980089Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}